A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder
Latest Information Update: 17 Aug 2020
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Allergan
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.
- 27 Nov 2017 New trial record